Abstract:Introduction Significant drug developments in immuno-oncology (IO) have been made in the last decade, which have led to clinical success in haematological cancers. To further unravel the potential of immunotherapies in solid cancers, relevant translational in vitro models are needed. Unlike traditional 2D assays with cancer cell lines, with the advancements in organoid technology immune responses can be monitored in a complex 3D co-culture of immune cells with tumor material, reflecting the original patient tumor morphology, genetics and transcriptomics. Using our biobank of over 650 patient-derived organoids (PDOs) from 21 different tissue types, a high content imaging (HCI)-based screening platform has been developed. This platform is highly effective for evaluating immunotherapy responses in vitro replicating the complex cellular interactions of the tumor microenvironment. Here, we assessed the immune sensitivity of 100 organoid models from 10 different cancer indications and tested the efficacy of T cell engagers and CAR-T cells. Methods and Materials PDOs and PDX-derived organoids (PDXO) from different indications (breast, cervical, colorectal, gallbladder, head and neck, lung, melanoma, mesothelioma, ovarian, and pancreatic) were cultured in a protein hydrogel. Isolated PBMCs from allogenic healthy donors were added to the 3D cultures to determine the immune-sensitivity of the models upon stimulation with superantigen or CD3/28 beads. Selected models were treated with EGFR targeting CAR-T cells or T cell engagers. HCI analysis was performed to extract morphometric information on immune cell infiltration and immune cell-mediated killing of the organoids. Additional cytokine analysis on the supernatants was performed by multiplex MSD. Results The clinical variability of sensitivity or resistance of cancer patients to immune cell-mediated killing was reflected in the 100 organoid models analyzed. Although most tested models demonstrated an increase in IFNγ levels upon treatment with EGFR targeting T cell engagers, these findings did not always correlate with increased killing of the organoids measured via HCI. These results correspond to the data obtained with EGFR targeting CAR-T cells. These CAR-T cells demonstrated an increased infiltration into the organoids, which resulted in reduced organoid volumes. Conclusion The preclinical in vitro model of organoid and immune cell co-cultures presented here allows for the functional testing of immunotherapies in a physiologically relevant assay via HCI. This platform enables the combination of classical biomarker analysis with read-outs on immune cell infiltration into organoids and subsequent organoid killing. This approach provides a deeper understanding of the mechanisms of action of the tested immunotherapies. With a large array of validated organoid models from various cancer indications, this innovative platform enhances preclinical testing of cancer immunotherapies, ultimately bringing the promise of these therapies to more patients. Citation Format: Saskia de Man, Sergei Chavez-Abiega, Tomas Veenendaal, Michelle Kop, Jarmil Hanrath, Daniel Okkes, Emma Spanjaard, Leo Price, Gera Goverse. High-Content Screening to Enhance the Preclinical Development of Immunotherapies, Validated for 100 Patient-Derived Organoids [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B040.

A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing

Abstract B057: An organoids-on-a-chip model to recapitulate and dissect the tumor microenvironment of PDAC

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Abstract 3857: A novel microfluidic platform for understanding the role of PDAC stroma in immune response

Organoid Modeling of the Tumor Immune Microenvironment

Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?

Abstract A023: Patient-Derived Organoid Cultures for Personalized Therapies and Targeted Drug Screening Applications

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring

Abstract B040: High-Content Screening to Enhance the Preclinical Development of Immunotherapies, Validated for 100 Patient-Derived Organoids

Abstract 1514: A novel workflow to assess the T-cell and patient-derived organoid interaction

A Pancreas Tumor Derived Organoid Study: from Drug Screen to Precision Medicine

Organoid Models for Precision Cancer Immunotherapy

Abstract 232: Multi-dimensional patient-derived organoid analysis highly correlates with progression-free survival of pancreatic cancer patients in a retrospective clinical trial

A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival

Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy

Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy

Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids

Abstract 2696: Tumor organoid and immune cells co-cultures to study myeloid cells-targeting immunotherapy

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

Abstract C046: Enhancing T cell infiltration and migration in the pancreatic tumor microenvironment